title: Surgery for liver metastases originating from sarcoma-case series.
abstract: BACKGROUND
  Liver metastases originating from various types of sarcoma are a rare reason for hepatic resection. So far, even multicentre studies do hardly provide statistically relevant sample sizes. Thus, review of available data can provide surgeons with useful information in similar cases. Therefore, this study can be regarded more as a contribution to this pool of data than as a stand-alone paper.
  
  
  METHODS
  The study includes 10 women and five men who underwent subtotal hepatic resection for solitary (n = 4) and multiple (n = 11) liver metastases originating from sarcoma. The median tumour diameter was 60 mm (range 20-200 mm).
  
  
  RESULTS
  Morbidity was 33%. One patient died within 30 days after surgery. Resection was complete (R0) in 67%. Median overall survival was 33.6 months, 5-year survival 27%. The use of Pringle manoeuvre was significantly associated with poorer outcome (p = 0.014) and shorter period of recurrence-free survival (p = 0.012). Diameter of liver lesion over 50 mm showed significantly shorter recurrence-free survival (p = 0.042).
  
  
  CONCLUSIONS
  Hepatic resection may be beneficial in patients with isolated sarcoma metastasis in the liver.
authors: Department of Orthopedics, Medical University of Graz, Auenbruggerplatz 6, 8036 Graz, Austria. max_zacherl@hotmail.com
authors: Maximilian
authors: M
authors: Zacherl
authors: Gerwin A
authors: GA
authors: Bernhardt
authors: Johannes
authors: J
authors: Zacherl
authors: Gerald
authors: G
authors: Gruber
authors: Peter
authors: P
authors: Kornprat
authors: Heinz
authors: H
authors: Bacher
authors: Hans-Jörg
authors: HJ
authors: Mischinger
authors: Reinhard
authors: R
authors: Windhager
authors: Raimund
authors: R
authors: Jakesz
authors: Thomas
authors: T
authors: Grünberger
mesh_terms: D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D018570:Risk Assessment; D012509:Sarcoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome